Table 6.
Sensitivity analyses for the association with relapse
| Rituximab Course | Sensitivity Analysis 1 | Sensitivity Analysis 2 | ||||||
|---|---|---|---|---|---|---|---|---|
| Redose Exclusively on the Basis of Disease Relapse (262 patients; 784 courses) | Individuals Receiving the Same Total No. of Courses of Rituximab | |||||||
| Two Courses (145 patients; 290 courses) | Three Courses (83 patients; 249 courses) | Four Courses (50 patients; 200 courses) | ||||||
| HRadj (95% CI) | P Value | HRadj (95% CI) | P Value | HRadj (95% CI) | P Value | HRadj (95% CI) | P Value | |
| Course 1 | 1 (reference) | — | 1 (reference) | — | 1 (reference) | — | 1 (reference) | — |
| Course 2 | 0.12 (0.09 to 0.17) | <0.001 | 0.12 (0.06 to 0.24) | <0.001 | 0.18 (0.10 to 0.33) | <0.001 | 0.13 (0.06 to 0.29) | <0.001 |
| Course 3 | 0.05 (0.03 to 0.08) | <0.001 | 0.05 (0.02 to 0.12) | <0.001 | 0.04 (0.01 to 0.11) | <0.001 | ||
| Course 4 | 0.03 (0.01 to 0.06) | <0.001 | 0.01 (0.00 to 0.02) | <0.001 | ||||
| Course 5 | 0.03 (0.01 to 0.06) | <0.001 | ||||||
| Course 6 | 0.03 (0.01 to 0.07) | <0.001 | ||||||
| Course ≥7 | 0.02 (0.01 to 0.07) | <0.001 | ||||||
Multiple mixed effects Cox regression model. Adjusted for dosing regimen, cumulative dose, duration of concomitant immunosuppression, sex, race and ethnicity, age at diagnosis, age at each rituximab episode, history of steroid resistance, disease severity, and number of previous immunosuppression treatments. HRadj, adjusted hazard ratio.